Neoplas Argon Jet was officially launched in Oman following successful clinical trials and a landmark symposium attended by over 150 healthcare professionals, including 80 Omani doctors specialising in infection control and paediatric surgery from Ministry of Health hospitals and the private sector.
The event celebrated a significant advancement in wound care and infection management, with top officials from the Ministry of Health present. The launch highlighted the introduction of the CE MDR-approved German technology, which uses cold atmospheric argon plasma to accelerate wound healing, stimulate tissue regeneration, and inactivate pathogens without pain or side effects.
Oman faces a 17 percent annual increase in diabetic cases, prompting medical professionals to explore innovative treatments for chronic wounds, including diabetic foot ulcers, dermatological lesions, and post-surgical infections. The technology was clinically evaluated at Khoula Hospital and Oman International Hospital before its official introduction.
The high-profile symposium in Muscat featured experts from Europe and Oman, providing scientific exchange, practical insights, and live demonstrations of the device. Fatma al Adawi, a podiatrist at Oman International Hospital, praised the symposium and emphasized the promising potential of cold plasma therapy in chronic wound management.
Saju George, Managing Director of Alfarsi National Enterprises, described the launch as a new chapter in wound care for diabetic foot ulcers and road accident victims in Oman. The development is the result of years of rigorous scientific collaboration involving neoplas med GmbH, the Leibniz Institute for Plasma Science and Technology, University Medical Center Greifswald, Charité – Universitätsmedizin Berlin, and other European research and industrial partners.
Notable speakers included Dr Christian Seebauer, Dr Aleksandra Szlachcic, and Prof. Dr Ralf Lobmann, who shared their expertise in plasma-based wound care, dermatology, and diabetic foot ulcers, respectively. Dr Klaus Ruhnau, COO of Neoplas Med GmbH, also addressed the audience, underscoring the growing global momentum behind cold plasma therapy.
